SCHEMBL5394237

SCHEMBL5394237

CC(C)NNC(=O)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.67
MAOA P21397 1/20 0.67
MAOB P27338 1/20 0.67
HPGD P15428 2/20 0.61
LMNA P02545 2/20 0.61
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 2/20 0.50
HDAC3 O15379 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
IDO1 P14902 1/20 0.50
ALOX15 P16050 1/20 0.50
HDAC1 Q13547 1/20 0.50
CA9 Q16790 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28948049 0.89 PTGS2 (0.54) PTGS2MAOAMAOBHPGDLMNA
SCHEMBL27939619 0.88 PTGS2 (0.53) PTGS2MAOAMAOBHPGDLMNA
SCHEMBL3869394 0.84 NPC1 (0.50) PTGS2MAOAMAOBHPGDLMNA
SCHEMBL8177990 0.84 NPC1 (0.50) PTGS2MAOAMAOBHPGDLMNA
SCHEMBL8761160 0.84 NPC1 (0.50) PTGS2MAOAMAOBHPGDLMNA
SCHEMBL21435752 0.84 HDAC1 (0.73) LMNANPC1RAB9AKDM4EHDAC3
Hydrochloric Acid SCHEMBL28948592 0.83 MAOA (0.53) PTGS2MAOAMAOBHPGDLMNA
Hydrochloric Acid SCHEMBL28020781 0.83 MAOA (0.53) PTGS2MAOAMAOBHPGDLMNA
SCHEMBL15486216 0.83 MAOA (0.67) PTGS2MAOAMAOBHPGDLMNA
Benmoxin SCHEMBL8759658 0.82 GPR139 (0.55) PTGS2MAOAMAOBHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015153516-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2015-10-08 WO claimed
US-8906952-B2 Indole derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic diseases containing same as active ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE & BIOTECHNOLOGY (KR) 2014-12-09 US claimed
US-20140057909-A1 Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2014-02-27 US claimed
US-11731934-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-08-22 US disclosed
US-11731934-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-08-22 US disclosed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 CN disclosed
CN-114621146-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-14 CN disclosed
CN-114605327-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-10 CN disclosed
CN-114591242-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-07 CN disclosed
CN-114573510-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-03 CN disclosed
EP-0361645-B1 ORGANIC HYDRAZINE DERIVATIVES FOR PHARMACEUTICAL USE ROHM AND HAAS COMPANY (US) 1993-09-29 EP disclosed
EP-0261755-B1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVES OF N'-SUBSTITUTED-N,N'-DIACYLHYDRAZINES ROHM AND HAAS COMPANY (US) 1992-12-16 EP disclosed
US-5117057-A Insecticidal N' substituted-N-N'-disubstituted-hydrazines ROHM AND HAAS COMPANY (US) 1992-05-26 US disclosed
EP-0253468-B1 SIX-MEMBERED HETEROCYCLIC DERIVATIVES OF N'SUBSTITUTED-N,N'-DIACYLHYDRAZINES ROHM AND HAAS COMPANY (US) 1991-11-06 EP disclosed
US-4985461-A Insecticidal N'-substituted-N,N'-diacylhydrazines ROHM AND HAAS COMPANY (US) 1991-01-15 US disclosed
EP-0361645-A2 Organic hydrazine derivatives for pharmaceutical use ROHM AND HAAS COMPANY (US) 1990-04-04 EP disclosed
CN-1039016-A N '-replacement-N, N '-two replaces the hydrazine insect repellent ROHM & HAAS (US) 1990-01-24 CN disclosed
EP-0261755-A2 Five-membered heterocyclic derivatives of N'-substituted-N,N'-Diacylhydrazines ROHM AND HAAS COMPANY (US) 1988-03-30 EP disclosed
EP-0253468-A2 Six-membered heterocyclic derivatives of N'substituted-N,N'-diacylhydrazines ROHM AND HAAS COMPANY (US) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731934-B2 HDAC inhibitor compounds and methods of treatment HDAC4, HDAC1, HDAC5 PTGS2 1327/4885MAOA 2728/4885MAOB 2262/4885
US-20140057909-A1 Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient DGAT2, DGAT1, DLAT PTGS2 1934/4885MAOA 501/4885MAOB 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.